Provided by Tiger Fintech (Singapore) Pte. Ltd.

TG Therapeutics

40.84
+3.7810.20%
Post-market: 41.000.1600+0.39%19:56 EDT
Volume:4.82M
Turnover:194.91M
Market Cap:6.41B
PE:-411.65
High:41.85
Open:37.50
Low:37.44
Close:37.06
Loading ...

TG Therapeutics Q4 2024 GAAP EPS $0.15, Inline, Sales $108.19M Beat $99.95M Estimate

Benzinga
·
03 Mar

TG Therapeutics Q4 Operating Income USD 29.949 Million

THOMSON REUTERS
·
03 Mar

TG Therapeutics Inc - Target Guidance of $540 Million in Total Global Revenue for 2025

THOMSON REUTERS
·
03 Mar

Risks To Shareholder Returns Are Elevated At These Prices For TG Therapeutics, Inc. (NASDAQ:TGTX)

Simply Wall St.
·
02 Mar

TG Therapeutics Inc expected to post earnings of 8 cents a share - Earnings Preview

Reuters
·
28 Feb

TG Therapeutics Announces Presentation of Data for Briumvi® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
27 Feb

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire
·
27 Feb

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire
·
26 Feb

Institutional investors in TG Therapeutics, Inc. (NASDAQ:TGTX) see US$243m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.
·
25 Feb

BRIEF-TG Therapeutics Announces Schedule Of Data Presentations For Briumvi® (Ublituximab) In Multiple Sclerosis At The Americas Committee For Treatment And Research In Multiple Sclerosis Annual Forum

Reuters
·
18 Feb

TG Therapeutics Announces Schedule of Data Presentations for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
18 Feb

How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months

Blockhead
·
12 Feb

MaxCyte enters strategic platform license with TG Therapeutics

TIPRANKS
·
12 Feb

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics

MT Newswires Live
·
12 Feb

Bank of America Securities Sticks to Its Sell Rating for TG Therapeutics (TGTX)

TIPRANKS
·
11 Feb

Confidence in TG Therapeutics’ Growth: Buy Rating Affirmed Amid Solid Financial Performance

TIPRANKS
·
29 Jan